Premium
Gene modification with integrin‐linked kinase improves function of endothelial progenitor cells in pre‐eclampsia in vitro
Author(s) -
Wang Fang,
Wang Ying,
Zhang Li,
Zou Li
Publication year - 2011
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.23236
Subject(s) - integrin linked kinase , angiogenesis , transfection , progenitor cell , protein kinase a , cancer research , endothelial progenitor cell , microbiology and biotechnology , kinase , chemistry , gene , biology , stem cell , cyclin dependent kinase 2 , biochemistry
Integrin‐linked kinase (ILK), a multifunctional serine–threonine protein kinase, has been shown to have implications for the treatment of ischemia vascular diseases by promoting angiogenesis in various tissues. However, whether this kinase has therapeutic potential in pre‐eclampsia is not well studied. In this report, we determined the changes in the production and action of ILK on endothelial progenitor cells (EPCs) isolated from patients with pre‐eclampsia. The effects of ILK transfection on proliferation, migration, and angiogenesis of EPCs were investigated. We showed that EPCs transfected with the ILK gene expressed high levels of ILK protein and mRNA. Transfection with ILK also enhanced the proliferative, migratory, and angiogenic capabilities of EPCs, and promoted the production of VEGF. These results suggest that ILK gene transfection is an effective approach to augment angiogenic properties of EPCs in vitro and providing basis for clinical cell‐based gene therapy in patients with pre‐eclampsia. J. Cell. Biochem. 112: 3103–3111, 2011. © 2011 Wiley Periodicals, Inc.